9.2425 -0.538 (-5.5%) | 03-28 13:54 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 13.99 | 1-year : | 16.34 |
Resists | First : | 11.97 | Second : | 13.99 |
Pivot price | 8.69 | |||
Supports | First : | 6.95 | Second : | 3.84 |
MAs | MA(5) : | 9.97 | MA(20) : | 7.8 |
MA(100) : | 4.76 | MA(250) : | 4.64 | |
MACD | MACD : | 1.3 | Signal : | 1.2 |
%K %D | K(14,3) : | 64 | D(3) : | 71.3 |
RSI | RSI(14): 60.3 | |||
52-week | High : | 11.97 | Low : | 2.38 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ LTRN ] has closed below upper band by 34.6%. Bollinger Bands are 205.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 20 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 10.49 - 10.54 | 10.54 - 10.58 |
Low: | 9.02 - 9.07 | 9.07 - 9.11 |
Close: | 9.7 - 9.79 | 9.79 - 9.85 |
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Tue, 26 Mar 2024
Is Lantern Pharma Inc (LTRN) Stock a Smart Investment Tuesday? - InvestorsObserver
Mon, 25 Mar 2024
Analyst Rating: Will Lantern Pharma Inc (LTRN) Stock Beat the Market? - InvestorsObserver
Tue, 19 Mar 2024
Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2023 Earnings Call Transcript - Yahoo Finance
Tue, 19 Mar 2024
Lantern Pharma's Triple Threat: Inflation, Global Tensions, and Pandemic Impacts Jeopardize Financial Health ... - TipRanks
Mon, 18 Mar 2024
Should You Buy Lantern Pharma Inc (LTRN) Stock After it Has Gained 46.84% in a Week? - InvestorsObserver
Mon, 18 Mar 2024
Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 11 (M) |
Shares Float | 8 (M) |
Held by Insiders | 15 (%) |
Held by Institutions | 22.5 (%) |
Shares Short | 68 (K) |
Shares Short P.Month | 69 (K) |
EPS | -1.48 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 3.81 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -21.9 % |
Return on Equity (ttm) | -33 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -1.67 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -14 (M) |
Levered Free Cash Flow | -9 (M) |
PE Ratio | -6.45 |
PEG Ratio | 0 |
Price to Book value | 2.47 |
Price to Sales | 0 |
Price to Cash Flow | -7.09 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |